AI English summary of an SEC filing — figures as filed
Thermo Fisher Scientific TMOThe company cited very strong productivity improvements as the primary driver of the increase in GAAP operating income margin and adjusted operating income margin in Q3 2025 and the first 9 months. It said strategic investments, the impact of tariffs and related foreign currency effects, and unfavorable business mix partially offset this in Q3.
Key points
AI summaryThe company cited very strong productivity improvements as the primary driver of the increase in GAAP operating income margin and adjusted operating income margin in Q3 2025 and the first 9 months. It said strategic investments, the impact of tariffs and related foreign currency effects, and unfavorable business mix partially offset this in Q3.
The company said it used $4.04 billion for acquisitions and $1.06 billion for purchases of property, plant and equipment during the first 9 months of 2025. It also said it repurchased $3.00 billion of common stock (2.1 million shares) and paid $0.47 billion in cash dividends.
The company said on September 1, 2025 it acquired Solventum Corporation's Purification and Filtration business within the Life Sciences Solutions segment, which became the company's filtration and separation business.
The company said its GAAP and adjusted tax rates in Q3 2025 were impacted by a tax benefit of $86 million from tax return reassessments. It said it expects its GAAP effective tax rate in 2025 to be between 8% and 10% and its adjusted tax rate to be approximately 10.5%.
Key figures
Quarter ended September 27, 2025
- Revenue
- $11.1B
- Operating income
- $1.9B
- Net income
- $1.6B
- EPS
- $4.27
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Operating Income Margin Changes in Q3 2025 and 9 Months: Company Explanation
The company cited very strong productivity improvements as the primary driver of the increase in GAAP operating income margin and adjusted operating income margin in Q3 2025 and the first 9 months. It said strategic investments, the impact of tariffs and related foreign currency effects, and unfavorable business mix partially offset this in Q3.
Source · Based on the MD&A text of the filing
2025 nine-month cash use: acquisitions, capex, buybacks, dividends
The company said it used $4.04 billion for acquisitions and $1.06 billion for purchases of property, plant and equipment during the first 9 months of 2025. It also said it repurchased $3.00 billion of common stock (2.1 million shares) and paid $0.47 billion in cash dividends.
Source · Based on the MD&A text of the filing
Solventum Purification and Filtration Business Acquisition on September 1, 2025
The company said on September 1, 2025 it acquired Solventum Corporation's Purification and Filtration business within the Life Sciences Solutions segment, which became the company's filtration and separation business.
Source · Based on the MD&A text of the filing
Tax Benefits and Full-Year Q3 2025 Tax Rate Outlook
The company said its GAAP and adjusted tax rates in Q3 2025 were impacted by a tax benefit of $86 million from tax return reassessments. It said it expects its GAAP effective tax rate in 2025 to be between 8% and 10% and its adjusted tax rate to be approximately 10.5%.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…